The Inhibitory Guanine Nucleotide-binding Regulatory Component of Adenylate Cyclase. Properties and Function of the Purified Protein
Overview
Authors
Affiliations
Treatment of membranes with islet activating protein (IAP), a toxin from Bordetella pertussis, results in abolition of GTP-dependent, receptor-mediated inhibition of adenylate cyclase. This appears to result from IAP-catalyzed ADP-ribosylation of a 41,000-Da membrane-bound protein. A protein with 41,000- and 35,000-Da subunits has been purified from rabbit liver membranes as the predominant substrate for IAP. This protein has now been shown to be capable of regulating membrane-bound adenylate cyclase activity of human platelets under various conditions. The characteristics of the actions of the IAP substrate are as follows. 1) Purified 41,000/35,000-Da dimer is capable of restoring the inhibitory effects of guanine nucleotides and the alpha 2-adrenergic agonist, epinephrine, on the adenylate cyclase activity of IAP-treated membranes. 2) The subunits of the dimer dissociate in the presence of guanine nucleotide analogs or A1(3+), Mg2+, and F-. The 41,000-Da subunit has a high affinity binding site for guanine nucleotides. 3) The resolved 35,000-Da subunit of the dimer mimics guanine nucleotide- and epinephrine-induced inhibition of adenylate cyclase. 4) The resolved (unliganded) 41,000-Da subunit stimulates adenylate cyclase activity and relieves guanine nucleotide- +/- epinephrine-induced inhibition of the enzyme. In contrast, the GTP gamma S-bound form of the 41,000-Da subunit inhibits adenylate cyclase activity, although with lower apparent affinity than does the 35,000-Da subunit. 5) The 35,000-Da subunit increases the rate of deactivation of Gs, the stimulatory regulatory protein of adenylate cyclase. In contrast, the 41,000-Da subunit can interact with Gs and inhibit its deactivation. These data strongly suggest that the IAP substrate is another dimeric, guanine nucleotide-binding regulatory protein and that it is responsible for inhibitory modulation of adenylate cyclase activity.
Discovery of small molecule Gq/11 protein inhibitors against uveal melanoma.
Ge Y, Deng J, Zhu J, Liu L, Ouyang S, Song Z Acta Pharm Sin B. 2022; 12(8):3326-3340.
PMID: 35967274 PMC: 9366314. DOI: 10.1016/j.apsb.2022.04.016.
Targeting G protein-coupled receptor signalling by blocking G proteins.
Campbell A, Smrcka A Nat Rev Drug Discov. 2018; 17(11):789-803.
PMID: 30262890 PMC: 6409483. DOI: 10.1038/nrd.2018.135.
Wang Q, Pronin A, Levay K, Almaca J, Fornoni A, Caicedo A FASEB J. 2017; 31(11):4734-4744.
PMID: 28687610 PMC: 5636707. DOI: 10.1096/fj.201700197RR.
Mooney J, Samson J, McHale N, Pappalarado K, Alpert J, Schildkraut J J Psychiatr Res. 2013; 47(6):706-11.
PMID: 23490066 PMC: 3669544. DOI: 10.1016/j.jpsychires.2013.02.005.
Suhaiman L, De Blas G, Obeid L, Darszon A, Mayorga L, Belmonte S J Biol Chem. 2010; 285(21):16302-14.
PMID: 20236935 PMC: 2871498. DOI: 10.1074/jbc.M109.072439.